TETRACYCLINE HYDROCHLORIDE | N050268 | STORZ OPHTHALMICS INC SUB AMERICAN CYANAMID CO
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| N/A | Not Yet Recruiting | Chih-An Shih, MD | 300 | 2026-09-01 → 2029-09-01 | |
| Phase 4 | Not Yet Recruiting | Qilu Hospital of Shandong University | 492 | 2026-09-01 → 2027-12-30 | |
| Phase 4 | Completed | National Taiwan University Hospital | 589 | 2015-07 → 2018-05 | |
| Phase 2 | Completed | Huntington Medical Research Institutes | 13 | 2011-09 → 2012-10 | |
| Phase 2 | Completed | M.D. Anderson Cancer Center | 5 | 1995-08-10 → 2001-10-08 | |
| N/A | Completed | Kaohsiung Veterans General Hospital. | 352 | 2015-02 → 2018-10 | |
| N/A | Completed | Seoul National University Bundang Hospital | 390 | 2014-07 → 2016-04 | |
| N/A | Completed | Kaohsiung Veterans General Hospital. | 51 | 2013-11 → 2017-10 | |
| Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 96 | 1997-09 | |
| Phase 4 | Completed | Shanghai Jiao Tong University School of Medicine | 424 | 2012-07 → 2012-10 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
5 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.